Technical Analysis for RPRX - Royalty Pharma plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical RPRX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Cup with Handle | Other | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Cup with Handle | Other | 0.88% | |
Narrow Range Bar | Range Contraction | 0.88% | |
NR7 | Range Contraction | 0.88% | |
Inside Day | Range Contraction | 0.88% | |
Oversold Stochastic | Weakness | 0.88% | |
Cup with Handle | Other | 1.78% | |
Down 3 Days in a Row | Weakness | 1.78% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Outside Day | about 23 hours ago |
Down 1% | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/17/2021
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 56.5 |
52 Week Low | 34.8 |
Average Volume | 2,870,954 |
200-Day Moving Average | 44.29 |
50-Day Moving Average | 45.79 |
20-Day Moving Average | 44.29 |
10-Day Moving Average | 42.72 |
Average True Range | 1.50 |
ADX | 20.15 |
+DI | 15.24 |
-DI | 26.25 |
Chandelier Exit (Long, 3 ATRs ) | 44.24 |
Chandelier Exit (Short, 3 ATRs ) | 45.93 |
Upper Bollinger Band | 48.40 |
Lower Bollinger Band | 40.17 |
Percent B (%b) | 0.26 |
BandWidth | 18.59 |
MACD Line | -1.16 |
MACD Signal Line | -1.02 |
MACD Histogram | -0.1404 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 43.77 | ||||
Resistance 3 (R3) | 43.64 | 43.02 | 43.52 | ||
Resistance 2 (R2) | 43.02 | 42.65 | 43.08 | 43.44 | |
Resistance 1 (R1) | 42.66 | 42.42 | 42.84 | 42.80 | 43.36 |
Pivot Point | 42.05 | 42.05 | 42.13 | 42.11 | 42.05 |
Support 1 (S1) | 41.69 | 41.67 | 41.87 | 41.82 | 41.26 |
Support 2 (S2) | 41.07 | 41.45 | 41.14 | 41.18 | |
Support 3 (S3) | 40.72 | 41.07 | 41.10 | ||
Support 4 (S4) | 40.85 |